$1.89
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The company is headquartered in Hingham, Massachusetts and currently employs 43 full-time employees. The company has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. The company specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. The company eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
Country

US

CEO

Mr. Harel Gadot

IPO date

1992

Employees

43

ISIN

US59503A2042

Key stats

Open

$1.89

Volume

480.53K

Market cap

$124.93M

Prev. close

$1.86

Impl / hst vl

-

Open interest

$0.00

$1.83

Day’s Range

$1.90

$1.60

52W Range

$2.86

Valuation

44
Valuation score
Fairly Valued
P/E
-
P/S
-
P/B
1.68
Current ratio
22.59
Debt / Equity
-0.05
ROE
-21.84%
Gross margin
-
Income growth
5.98%
FCF growth
36.43

Analysts estimates

Consensus rating
Buy

The average rating from top 6 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$7.14
The top 5 analysts forecasts that 12-month price may increase by 277.78%, with a low of $4.04 and a high of $12.60
$4.04
Low
$7.14
Avg
$12.60
High
Current price

Earnings

Q1 ‘26 revenue
$105.00K
Q1 ‘26 net income
-$3.67M
Revenue
Net income
Previous EPS
-$0.05
Estimate EPS
-$0.09
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply